243 related articles for article (PubMed ID: 8768004)
21. Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin.
Bow EJ; Gallant G; Williams GJ; Woloschuk D; Shore TB; Rubinger M; Schacter BA
Cancer; 1998 Oct; 83(7):1344-54. PubMed ID: 9762935
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
Sung WJ; Kim DH; Sohn SK; Kim JG; Baek JH; Jeon SB; Moon JH; Ahn BM; Lee KB
Jpn J Clin Oncol; 2005 Oct; 35(10):612-6. PubMed ID: 16172175
[TBL] [Abstract][Full Text] [Related]
23. [Diagnostics and therapy of acute myeloid leukemia].
Kern W; Haferlach T; Schoch C; Hiddemann W
Dtsch Med Wochenschr; 2002 Oct; 127(42):2208-13. PubMed ID: 12397550
[No Abstract] [Full Text] [Related]
24. Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia.
Rizzieri DA; O'Brien JA; Broadwater G; Decastro CM; Dev P; Diehl L; Beaven A; Lagoo A; Gockerman JP; Chao NJ; Moore JO
Cancer; 2009 Jul; 115(13):2922-9. PubMed ID: 19452542
[TBL] [Abstract][Full Text] [Related]
25. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
[TBL] [Abstract][Full Text] [Related]
26. "3+7" therapy for the treatment of acute myeloid leukemia. CON.
Estey EH
Clin Adv Hematol Oncol; 2005 Feb; 3(2):129-132, 141. PubMed ID: 16173152
[No Abstract] [Full Text] [Related]
27. Impetiginous lesions in recurrent AML.
Morris DJ; Lyman GH; Muus C
Hosp Pract (Off Ed); 1989 Mar; 24(3A):153-6. PubMed ID: 2494201
[No Abstract] [Full Text] [Related]
28. [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].
Reinhardt D; Hempel G; Fleischhack G; Schulz A; Boos J; Creutzig U
Klin Padiatr; 2002; 214(4):188-94. PubMed ID: 12165900
[TBL] [Abstract][Full Text] [Related]
29. [Acute myeloid leukemias in elderly patients].
Parovichnikova EN; Savchenko VG
Ter Arkh; 1990; 62(7):148-54. PubMed ID: 2251656
[No Abstract] [Full Text] [Related]
30. Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial.
Thomas X; Elhamri M; Chelghoum Y; Reman O; Arnaud P; Raffoux E; Le QH; Tavernier E; Dombret H; Michallet M
Ann Hematol; 2005 Jun; 84(6):376-82. PubMed ID: 15782343
[TBL] [Abstract][Full Text] [Related]
31. Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.
Tallman MS; Lee S; Sikic BI; Paietta E; Wiernik PH; Bennett JM; Rowe JM
Cancer; 1999 Jan; 85(2):358-67. PubMed ID: 10023703
[TBL] [Abstract][Full Text] [Related]
32. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.
Wrzesień-Kuś A; Robak T; Wierzbowska A; Lech-Marańda E; Pluta A; Wawrzyniak E; Krawczyńska A; Kuliczkowski K; Mazur G; Kiebiński M; Dmoszyńska A; Wach M; Hellmann A; Baran W; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S;
Ann Hematol; 2005 Sep; 84(9):557-64. PubMed ID: 15856358
[TBL] [Abstract][Full Text] [Related]
33. Occurrence and therapy of secondary acute myeloid leukaemia in two HIV-infected patients.
Hengge UR; Schultewolter T; Uppenkamp T
AIDS; 1998 Jan; 12(2):221-2. PubMed ID: 9468375
[No Abstract] [Full Text] [Related]
34. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
35. [Complications associated with short-term intensive consolidation chemotherapy for adults with acute myelogenous leukemia].
Nagata K; Abe Y; Hatanaka T; Ito T; Saito M; Ono Y; Kamiya O; Ohara K
Gan To Kagaku Ryoho; 1993 Sep; 20(12):1869-72. PubMed ID: 8379681
[No Abstract] [Full Text] [Related]
36. The treatment of acute myeloid leukemia with mitoxantrone, etoposide and low-dose cytarabine in elderly patients - a report of Polish Acute Leukemia Group (PALG) phase II study.
Wrzesien-Kus A; Robak T; Jamroziak K; Wierzbowska A; Dmoszynska A; Adamczyk-Cioch M; Kuliczkowski K; Mazur G; Holowiecki J; Konopka L; Maj S; Marianska B; Zawilska K;
Neoplasma; 2002; 49(6):405-11. PubMed ID: 12584589
[TBL] [Abstract][Full Text] [Related]
37. The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia.
Vulaj V; Perissinotti AJ; Uebel JR; Nachar VR; Scappaticci GB; Crouch A; Bixby DL; Burke PW; Maillard I; Talpaz M; Marini BL
Leuk Res; 2018 Jul; 70():91-96. PubMed ID: 29908418
[TBL] [Abstract][Full Text] [Related]
38. Elderly acute myeloid leukemia: patients are not all the same.
Schaich M
Haematologica; 2004 Mar; 89(3):261-3. PubMed ID: 15020259
[No Abstract] [Full Text] [Related]
39. Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
Kröger N; Damon L; Zander AR; Wandt H; Derigs G; Ferrante P; Demirer T; Rosti G; ; ;
Bone Marrow Transplant; 2003 Dec; 32(12):1153-7. PubMed ID: 14647269
[TBL] [Abstract][Full Text] [Related]
40. [Results of treatment and analysis of remission induction failures in acute promyelocytic leukemia].
Ashida T; Ishikawa H; Urase F; Shimotsuma N; Sato M; Sueyoshi A; Tsubaki K; Irimajiri K; Horiuchi A
Rinsho Ketsueki; 1988 Feb; 29(2):109-15. PubMed ID: 3164421
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
